Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan

The data support Oncothyreon’s plans to initiate a blinded, randomized, … of Texas MD Anderson Cancer Center and one of the authors of both presentations.